Breast Cancer Coverage From Every Angle
Editor:
William J. Gradishar, MD
Advertisement
Advertisement

Videos

Kathy S. Albain, MD, on Breast Cancer, Ethnicity, and Clinical Outcomes: NCCN Perspectives on the TAILORx Trial

Harold J. Burstein, MD, PhD, and Daniel F. Hayes, MD, on Breast Cancer With Positive Lymph Nodes: Treatment Controversy and the NCCN Clinical Guidelines

Charles von Gunten, MD, PhD, on Protecting Opioid Access: NCCN Guideline Recommendations

Marleen Kok, MD, PhD, on Luminal Breast Cancer: Immunotherapy Strategies

Sherene Loi, MD, PhD, and Lisa A. Carey, MD, on TNBC: Combination Immune Checkpoint Inhibitor Therapy

Matthew J. Ellis, MB, BChir, PhD, on Breast Cancer: Neoadjuvant Endocrine Therapy and Guideline Recommendations

Andrew D. Seidman, MD, and Aditya Bardia, MD, MPH, on Metastatic Breast Cancer: Findings on an Antibody-Drug Conjugate

Elizabeth A. Mittendorf, MD, PhD, and Lisa A. Carey, MD, on Breast Cancer: Commentary on the TAILORx Trial

Helena Margaret Earl, MBBS, PhD, on Early Breast Cancer: Results From the Persephone Trial

Anthony D. Elias, MD, on Triple-Negative Breast Cancer: Guidelines Update

William J. Gradishar, MD, on Balancing Treatment and Quality of Life

William J. Gradishar, MD, on Hormone-Sensitive Breast Cancer: Guideline Updates

Anthony D. Elias, MD, on Balancing Treatment and Quality of Life

Crystal S. Denlinger, MD, and Ann H. Partridge, MD, MPH, on Making Sense of Guidelines and Guidance

A Patient’s Story: NCCN Guidelines for Patients® Helped Me Ask The Right Questions

A Patient's Story: How NCCN Guidelines for Patients® Helped Me and My Caregiver

Meredith M. Regan, ScD, on Early Breast Cancer: Update on the TEXT and SOFT Trials

Aditya Bardia, MD, MPH, on Triple-Negative Breast Cancer: Trial Results of IMMU-132

Ruth M. O’Regan, MD, and Douglas Yee, MD: Results From the I-SPY2 Trial

Ruth M. O’Regan, MD, and Debu Tripathy, MD, on HR+, HER2– Breast Cancer: Results From the MONALEESA-7 Trial

Hope S. Rugo, MD, on Locally Recurrent or Metastatic Breast Cancer: Results of a CALGB/NCCTG Trial

G. Thomas Budd, MD, on Choosing Neoadjuvant Treatment for Patients With Early Breast Cancer

Cristina Saura, MD, on Choosing Neoadjuvant Treatment for Patients With Early Breast Cancer

Sibylle Loibl, MD, PhD, on Managing Neutropenia Associated with CDK Inhibitors

Declan Walsh, MD, on Opioid-Induced Nausea and Vomiting: Tips for Daily Practice

Cristina Saura, MD, on Breast Cancer: Results from the LORELEI Trial

William J. Gradishar, MD, on Triple-Negative Breast Cancer: Expert Perspective on the KEYNOTE-086 Trial Results

Benjamin O. Anderson, MD, on NCCN’s Resource-Stratified Framework: Expert Perspective

Gunter von Minckwitz, MD, on HER2+ Breast Cancer: Results From the APHINITY Trial

William J. Gradishar, MD, and Mark E. Robson, MD, on HER2-Negative Breast Cancer: Results From the OlympiAD Trial

George W. Sledge, MD, on HR+/HER2– Breast Cancer: Results From the MONARCH 2 Trial

William J. Gradishar, MD, and Rita Nanda, MD, on High-Risk Breast Cancer: Results From the I-SPY 2 Trial

William J. Gradishar, MD, on Endocrine Therapy for Breast Cancer

William J. Gradishar, MD, and Kilian E. Salerno, MD, on Evolving Radiation Therapy Recommendations

Lee S. Schwartzberg, MD, on Biomarkers and Gene Assays

George Somlo, MD, on Breast Cancer and TILs: Treatment Challenges

William J Gradishar, MD, on NCCN Guidelines: Process, Evolution, and Clinical Practice

Harold J. Burstein, MD, PhD, and William J. Gradishar, MD, on ER+ Breast Cancer: Coming Changes in Treatment

The JNCCN Spotlight

Welcome to JNCCN 360

Copyright © 2018 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.